 |
|
|
| |
ViiV HEALTHCARE TO PRESENT PHASE IIIB DATA COMPARING DOVATO WITH BIKTARVY IN TREATMENT-NAÏVE ADULTS; ALONGSIDE INSTI-POWERED LONG-ACTING INJECTABLE INNOVATION AT AIDS 2026
|
| |
| |
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy in treatment-naÏve adults living with HIV
Real-world OPERA data continues to strengthen the evidence base for Cabenuva, the only complete long-acting injectable HIV treatment regimen
Six-month results from the CLARITY study will report participant experience and acceptability of long-acting cabotegravir versus lenacapavir injections after a single dose in HIV-negative adults
London, 21 July 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its integrase strand transfer inhibitor (INSTI)-focused portfolio, including long-acting (LA) medicines and pipeline momentum, to be presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from 26-31 July.
VOGUE daily orals phase IIIb data will compare ViiV Healthcare’s established 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in treatment-naÏve adults living with HIV1
Additional data from VOGUE will examine the study population demographics, including adults with high viral loads.2
A pooled analysis across clinical trials will examine on-study viraemic events and outcomes for DTG/3TC compared with 3-drug regimens.3
Data evaluating long-acting injectable HIV treatment, including late-breaking LATA results and OPERA real-world data, will add to the evidence base for cabotegravir + rilpivirine long acting (CAB+RPV LA)
Late-breaking week 96 results from the LATA study, led by University College London, will evaluate the efficacy, safety and acceptability of CAB+RPV LA versus daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in virologically suppressed adolescents living with HIV across sub-Saharan Africa.4
New data from OPERA will be presented, including from the US-based cohort, comparing the virologic effectiveness of injectable CAB+RPV LA versus daily oral BIC/FTC/TAF in virologically suppressed adults living with HIV.5,6,7
Week 96 results from the IMPALA study, led by London School of Hygiene and Tropical Medicine, will provide new insights into the use of CAB+RPV LA in adults living with HIV with prior adherence challenges in sub-Saharan Africa, including treatment outcomes over time.8
Data from Ask Us Europe, a community co-produced survey, led by an academic team in London, will explore whether people living with HIV across Europe are having meaningful and equitable conversations with healthcare providers about long-acting HIV treatment options.9,10,11
CAB LA for pre-exposure prophylaxis (PrEP) data, including CLARITY results comparing CAB LA with lenacapavir, will inform how long-acting injectable prevention options are used in practice
Six-month results from the phase I CLARITY study will report participant experience and acceptability of CAB LA versus lenacapavir injections after a single dose, as well as late-breaking data on participant-reported outcomes, informing decision-making when initiating long-acting injectables for PrEP.12,13
CAPTIVATE results will describe real-world use, acceptability and delivery of CAB LA for PrEP in routine US clinical practice.14,15
Updated PrEPFACTS results will describe real-world use and adherence patterns for CAB LA for PrEP in the US, using healthcare administrative claims data.16
EXTEND 4M will evaluate a new long-acting dosing candidate for HIV prevention
Baseline data from the phase IIb registrational EXTEND 4M trial will describe the population being evaluated in the first study evaluating a new formulation of CAB LA dosed three times a year for HIV PrEP.17 This study builds on the established evidence for CAB LA for PrEP dosed six times a year and will assess the pharmacokinetics, safety and tolerability of the new CAB LA formulation.
full press release
Download the PDF here
https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2026/july/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy/
gmthreadidentifier::end --
|
| |
|
|
|
|
|
